昆药集团
(600422)
| 流通市值：63.81亿 | | | 总市值：63.81亿 |
| 流通股本：7.57亿 | | | 总股本：7.57亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 836,158,258.4 | 6,575,214,133.55 | 4,751,206,077.58 | 3,351,347,279.45 |
| 营业收入 | 836,158,258.4 | 6,575,214,133.55 | 4,751,206,077.58 | 3,351,347,279.45 |
| 二、营业总成本 | 1,005,316,275.73 | 6,335,560,770.88 | 4,530,354,855.67 | 3,100,213,351.06 |
| 营业成本 | 647,460,348.24 | 4,042,284,632.19 | 2,878,309,131.15 | 2,015,846,300.01 |
| 税金及附加 | 6,914,899.7 | 60,455,242.15 | 48,161,680.66 | 34,249,303.52 |
| 销售费用 | 241,421,364.92 | 1,708,462,496.46 | 1,231,760,848.77 | 808,861,492.81 |
| 管理费用 | 83,628,103.79 | 378,558,162.68 | 265,015,043.54 | 174,256,035.83 |
| 研发费用 | 15,270,107.62 | 102,548,170.75 | 72,802,481 | 43,891,351.15 |
| 财务费用 | 10,621,451.46 | 43,252,066.65 | 34,305,670.55 | 23,108,867.74 |
| 其中:利息费用 | 8,663,197.43 | 50,588,546.01 | 40,316,540.49 | 27,472,873.34 |
| 其中:利息收入 | 701,643.89 | 10,000,393.17 | 6,203,569.61 | 4,762,912.53 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 40,566,944.52 | 108,913,808.46 | 120,657,532.8 | 1,445,663.76 |
| 加:投资收益 | 19,627,546.81 | 62,011,166.44 | 1,431,001.38 | -694,593.72 |
| 资产处置收益 | 438,657.93 | 673,035.91 | -9,007.94 | -757.86 |
| 资产减值损失(新) | -12,774,711.76 | -31,589,763.74 | -8,226,530.19 | -4,752,967.11 |
| 信用减值损失(新) | -17,747,958.82 | -23,459,591.86 | -18,365,269.8 | -7,289,627.92 |
| 其他收益 | 5,046,325.73 | 92,305,932.18 | 62,959,351.95 | 59,962,336.87 |
| 四、营业利润 | -134,001,212.92 | 448,507,950.06 | 379,298,300.11 | 299,803,982.41 |
| 加:营业外收入 | 291,931.28 | 26,279,181.57 | 4,242,241.1 | 2,351,220.12 |
| 减:营业外支出 | 4,581,606.17 | 1,229,292.96 | 5,119,490.52 | 3,214,933.56 |
| 五、利润总额 | -138,290,887.81 | 473,557,838.67 | 378,421,050.69 | 298,940,268.97 |
| 减:所得税费用 | 6,556,763.98 | 54,504,976.99 | 55,016,298.7 | 49,019,448.21 |
| 六、净利润 | -144,847,651.79 | 419,052,861.68 | 323,404,751.99 | 249,920,820.76 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -144,847,651.79 | 419,052,861.68 | 323,404,751.99 | 249,920,820.76 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -141,783,891.37 | 349,940,750.73 | 269,367,794.35 | 198,355,219.85 |
| 少数股东损益 | -3,063,760.42 | 69,112,110.95 | 54,036,957.64 | 51,565,600.91 |
| 扣除非经常损益后的净利润 | -190,227,125.75 | 107,110,148.34 | 117,130,145.27 | 151,101,472.65 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.19 | 0.46 | 0.36 | 0.26 |
| (二)稀释每股收益 | -0.19 | 0.46 | 0.36 | 0.26 |
| 八、其他综合收益 | -1,449,310.54 | -12,037,693.62 | 29,191.86 | 1,987,515.85 |
| 归属于母公司股东的其他综合收益 | -1,368,890.02 | -12,213,098.61 | -193,239.14 | 2,048,607.45 |
| 九、综合收益总额 | -146,296,962.33 | 407,015,168.06 | 323,433,943.85 | 251,908,336.61 |
| 归属于母公司股东的综合收益总额 | -143,152,781.39 | 337,727,652.12 | 269,174,555.21 | 200,403,827.3 |
| 归属于少数股东的综合收益总额 | -3,144,180.94 | 69,287,515.94 | 54,259,388.64 | 51,504,509.31 |
| 公告日期 | 2026-04-25 | 2026-03-20 | 2025-10-25 | 2025-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |